These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 9311391

  • 1. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.
    Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, Halsall PJ, Hartung E, Heffron JJ, Heytens L, Kozak-Ribbens G, Kress H, Krivosic-Horber R, Lehmann-Horn F, Mortier W, Nivoche Y, Ranklev-Twetman E, Sigurdsson S, Snoeck M, Stieglitz P, Tegazzin V, Urwyler A, Wappler F.
    Acta Anaesthesiol Scand; 1997 Sep; 41(8):955-66. PubMed ID: 9311391
    [Abstract] [Full Text] [Related]

  • 2. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
    Mortier W, Breucking E.
    Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
    [Abstract] [Full Text] [Related]

  • 3. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
    Hartung E, Koob M, Anetseder M, Schoemig P, Krauspe R, Hogrefe G, Engelhardt W.
    Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
    [Abstract] [Full Text] [Related]

  • 4. Classification of malignant hyperthermia-equivocal patients by 4-chloro-M-cresol.
    Gilly H, Musat I, Fricker R, Bittner RE, Steinbereithner K, Kress HG.
    Anesth Analg; 1997 Jul; 85(1):149-54. PubMed ID: 9212139
    [Abstract] [Full Text] [Related]

  • 5. Effects of the phosphodiesterase-III inhibitor enoximone on skeletal muscle specimens from malignant hyperthermia susceptible patients.
    Fiege M, Wappler F, Scholz J, Weisshorn R, von Richthofen V, Schulte am Esch J.
    J Clin Anesth; 2000 Mar; 12(2):123-8. PubMed ID: 10818326
    [Abstract] [Full Text] [Related]

  • 6. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
    Ording H, Bendixen D.
    Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
    [Abstract] [Full Text] [Related]

  • 7. An analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia.
    Hopkins PM, Ellis FR, Halsall PJ, Stewart AD.
    Anesth Analg; 1997 Mar; 84(3):648-56. PubMed ID: 9052318
    [Abstract] [Full Text] [Related]

  • 8. Is there a link between exertional heat stroke and susceptibility to malignant hyperthermia?
    Sagui E, Montigon C, Abriat A, Jouvion A, Duron-Martinaud S, Canini F, Zagnoli F, Bendahan D, Figarella-Branger D, Brégigeon M, Brosset C.
    PLoS One; 2015 Mar; 10(8):e0135496. PubMed ID: 26258863
    [Abstract] [Full Text] [Related]

  • 9. Predictive factors of the contracture test for diagnosing malignant hyperthermia in a Brazilian population sample: a retrospective observational study.
    de Mello JM, Andrade PV, Santos JM, Oliveira ASB, Vainzof M, do Amaral JLG, Almeida da Silva HC.
    Braz J Anesthesiol; 2023 Mar; 73(2):145-152. PubMed ID: 35835312
    [Abstract] [Full Text] [Related]

  • 10. [Diagnosis of susceptibility to malignant hyperthermia with an in vitro contracture test with the phosphodiesterase iii inhibitor enoximone].
    Fiege M, Wappler F, Scholz J, von Richthofen V, Brinken B, Schulte am Esch J.
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Sep; 33(9):557-63. PubMed ID: 9787864
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Results of in vitro contracture testing of both parents of malignant hyperthermia susceptible probands.
    Islander G, Bendixen D, Ranklev-Twetman E, Ording H.
    Acta Anaesthesiol Scand; 1996 May; 40(5):579-84. PubMed ID: 8792888
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Determination of a positive malignant hyperthermia (MH) disposition without the in vitro contracture test in families carrying the RYR1 Arg614Cys mutation.
    Rueffert H, Olthoff D, Deutrich C, Froster UG.
    Clin Genet; 2001 Aug; 60(2):117-24. PubMed ID: 11553045
    [Abstract] [Full Text] [Related]

  • 18. 4-Chloro-m-cresol test--a possible supplementary test for diagnosis of malignant hyperthermia susceptibility.
    Ording H, Glahn K, Gardi T, Fagerlund T, Bendixen D.
    Acta Anaesthesiol Scand; 1997 Sep; 41(8):967-72. PubMed ID: 9311392
    [Abstract] [Full Text] [Related]

  • 19. C1840-T mutation in the human skeletal muscle ryanodine receptor gene: frequency in northern German families susceptible to malignant hyperthermia and the relationship to in vitro contracture response.
    Steinfath M, Singh S, Scholz J, Becker K, Lenzen C, Wappler F, Köchling A, Roewer N, Schulte am Esch J.
    J Mol Med (Berl); 1995 Jan; 73(1):35-40. PubMed ID: 7633940
    [Abstract] [Full Text] [Related]

  • 20. [Evaluation of malignant hyperthermia episodes with the Clinical Grading Scale].
    von Richthofen V, Wappler F, Scholz J, Fiege M, Schulte am Esch J.
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Apr; 33(4):244-9. PubMed ID: 9617423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.